| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-02-02 | Leo Pharma (Denmark) 4SC (Germany) | oral treatment for inflammatory skin diseases | skin diseases, psoriasis | R&D |
Autoimmune diseases - Dermatological diseases | R&D agreement |
| 2013-01-31 | Antitope (UK) Rottapharma Biotech (Italy) | musculoskeletal disorders | R&D |
Musculoskeletal diseases | R&D agreement | |
| 2013-01-29 | 4-Antibody AG (Switzerland) Ludwig Institute for Cancer Research (LICR) Recepta Biopharma (Brazil) | three antibody products targeting immune checkpoints important in cancer therapy | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-01-29 | GenoSplice (France) Institut Curie (France) Curie Cancer (France) | cancer genomics | cancer, prostate cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2013-01-29 | Lophius Biosciences (Germany) Oxford Immunotec (UK) | intellectual property related to T-cell based assays and to UREA and SPOT® technologies | collaboration |
Infectious diseases - Immunological diseases | Collaboration agreement | |
| 2013-01-29 | Merck Serono (Germany) Feinstein Institute (USA) | antibodies for the treatment of systemic lupus erythematosus (SLE) | systemic lupus erythematosus (SLE) | R&D |
Autoimmune diseases | R&D agreement |
| 2013-01-28 | GSK (UK) Biological E Limited (India) | six-in-one combination paediatric vaccine | polio, diphtheria, tetanus, whooping cough (whole cell pertussis), hepatitis B, and Haemophilus influenzae type b infection | joint-venture |
Infectious diseases | Joint-venture agreement |
| 2013-01-25 | mondoBIOTECH (Switzerland) Pierrel (Italy) | |||||
| 2013-01-25 | AstraZeneca (UK) Orexo (Sweden) | OX-CLI program (arachidonic acid-based advanced program) | respiratory diseases | R&D |
Respiratory diseases | R&D agreement |
| 2013-01-24 | Elekta (USA) Philips (The Netherlands) MD Anderson Cancer Center (USA) | image-guided treatment technology for cancer care | cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2013-01-24 | Ipsen (France) Inspiration Biopharmaceuticals (USA) Baxter (USA) | OBI-1, a recombinant porcine factor VIII (rpFVIII) and Ipsen’s industrial facility in Milford | congenital hemophilia A with inhibitors and acquired hemophilia A | asset purchase |
Hematologic diseases - Genetic diseases | Product acquisition |
| 2013-01-22 | Imaxio (France) D&A Pharma (France) | Trolovol® (D-penicillamine) | Wilson's disease | product acquisition | Metabolic diseases - Rare diseases | Product acquisition |
| 2013-01-22 | Domain Therapeutics (France) Prexton Therapeutics (Switzerland) | mGluR4 PAMs (Positive Allosteric Modulators) | Parkinson's disease | licensing |
Neurodegenerative diseases - CNS diseases | Licensing agreement |
| 2013-01-22 | Dezima Pharma (The Netherlands) Mitsubishi Tanabe Pharma (Japan) | cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) | dyslipidemia | licensing |
Cardiovascular diseases | Licensing agreement |
| 2013-01-21 | Merial (France) Vitamfero (France) | new production animal antiparasitic vaccines | development |
Veterinary medicine | Development agreement | |
| 2013-01-18 | Apeiron Biologics (Austria) Paladin Labs (Canada) | APN311 | neuroblastoma | licensing |
Cancer - Oncology | Licensing agreement |
| 2013-01-17 | Laboratoires Pierre Fabre (France) Maruho (Japan) | oral formulation of an undisclosed paediatric beta-blocker | severe infantile haemangioma | development |
Dermatological diseases | Development agreement |
| 2013-01-17 | Covance (USA) the Royal Liverpool and Broadgreen University Hospitals NHS Trust (UK) | early clinical trials | clinical research |
Clinical research agreement | ||
| 2013-01-16 | Adaptimmune (UK) NeoStem (USA) Progenitor Cell Therapy (USA) | NYESO-1c259-T cell therapy product | manufacturing |
Cancer - Oncology | Production agreement | |
| 2013-01-15 | Royal DSM (The Netherlands) Amgen (USA) | XD® high cell density technology | licensing |
Licensing agreement |
